ArticleMolecular biology reports2025
Ectopic expression of miR-34a/-328 sensitizes breast cancer stem cells to gamma rays/doxorubicin by BCL2/ABCG2 targeting.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- Hypericin-loaded small extracellular vesicles increase photodynamic therapy and remodel miRNA-mRNA axes in AGS gastric cancer cells.Scientific reports · 2026Article
- Epigenetic crosstalk between stem cells and tumors: mechanisms and emerging perspectives.American journal of stem cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn the present study, we aim to identify novel molecular targets for sensitizing Breast cancer stem cells (BCSCs) to common antitumor treatments. MicroRNAs (miRNAs) play key roles in pivotal cellular processes. Therefore, modulating the expression of these miRNAs may lead to increased sensitivity of BCSCs to current treatments or overcome their therapeutic resistance. Due to their pivotal roles in the regulation of apoptosis (via BCL2) and chemoresistance (via ABCG2) and their differential expression in BCSCs (compared to non-BCSCs), miR-34a and miR-328 were selected for analysis.
methodsBCSCs were propagated and characterized. Then, the expression levels of miRNAs, which are associated with treatment resistance (miR-21, -34a, -328, -128, -200c, Let-7i), were quantified in BCSCs and non-BCSCs before and after treatment with doxorubicin (DOX) and radiation. BCSCs were subsequently transduced with recombinant lentiviruses that contained miR-34a or miR-328 to sensitize these cells to DOX- and radio-treatment, respectively. The effects of miR-34a or miR-328 overexpression on apoptosis induction after irradiation or DOX treatment were assessed by flow cytometry analysis.
resultsEctopic expression of miR-34a or miR-328 in BCSCs, respectively, decreased the BCL2 and ABCG2 expression levels compared to untreated cells. Furthermore, overexpression of miR-34a or miR-328 in BCSCs led to increased susceptibility to apoptosis induced by radiation or DOX treatment, respectively.
conclusionIt could be concluded that miR-34a or miR-328 could effectively increase radiation- or DOX-induced cell apoptosis by negatively regulating Bcl-2 or ABCG2 expression levels in BCSCs, respectively. Hence, ectopic expression of these miRNAs could sensitize BCSCs to irradiation and DOX treatment.
Indexed as
Identifiers
40402331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.